Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amgen, Inc.    AMGN   US0311621009


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

04/24/2012 | 04:40pm US/Eastern

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481;

React to this article
Latest news on AMGEN, INC.
1d ago AMGEN : Announces 30 Percent Increase In 2015 First Quarter Dividend
1d ago AMGEN : And AstraZeneca To Present Results From Phase 3 AMAGINE-1⿢ Study ..
3d ago AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
3d ago AMGEN : E.R. Squibb & Sons Assigned Patent
6d ago ASTRAZENECA : and Amgen to present detailed results from Phase III AMAGINE-1 stu..
7d ago AMGEN : And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study E..
7d ago AMGEN : Updates on Talimogene Laherparepvec Trial
12/10 AMGEN : FDA approves Amgen's XGEVA to treat Hypercalcemia
12/10 AMGEN : Releases Data from Phase 2 Blincyto
12/10 AMGEN : E.R. Squibb & Sons, Amgen Assigned Patent
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes